Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Biotech Growth Trust (the) Plc LSE:BIOG London Ordinary Share GB0000385517 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  10.00 0.74% 1,358.00 1,340.00 1,352.00 1,336.00 1,330.00 1,336.00 58,756 16:35:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Equity Investment Instruments 1.0 0.1 -0.2 - 565

Biotech Growth Share Discussion Threads

Showing 51 to 75 of 350 messages
Chat Pages: 14  13  12  11  10  9  8  7  6  5  4  3  Older
DateSubjectAuthorDiscuss
01/8/2013
21:47
rbdc1, Over the past year, this has traded in a range between a 5% discount and 4% premium. So this could be seen as a buying opportunity. www.trustnet.com/Webservices/Charting.asmx/GetDiscountPremiumChart?width=650&height=250&unitCode=AKR0&span=12
madmix
01/8/2013
18:10
Odd that BIOG is now 4% below its NAV when it used to trade at a slight premium...
rbdc1
26/7/2013
21:25
For an actively managed fund, BIOG seems to be lagging the major (passive) biotech etfs (ibb/fbt etc) over the past few months which is dismal given fund manager's hefty fees and annual management charges.
rford78
17/7/2013
08:56
Prognosis: Healthy earnings for pharma, biotech www.cnbc.com/id/100890557
protean
14/7/2013
10:53
The sector is on a roll: dealbook.nytimes.com/2013/07/11/biotech-companies-surge-as-investors-flock-to-them/
protean
08/7/2013
14:11
IBT was less volatile over the last few weeks.
davebowler
06/7/2013
08:35
Had a skip through Annual Report and accounts. Just keep holding. In fact should have certainly added on the dip a few weeks ago.
philo124
20/5/2013
16:20
harry switched to IBT in mid march for a 13.5% return v 9.5% for BIOG over the same period, not earth shattering, but the 11% NAV discount should close further if IMO the sector index continues to rise. This will provide a degree of leverage to the share price
rogerrail
20/5/2013
15:47
Shares going well-as long as USA confidence keeps going-its the best performing I.Trust share over last 2/3 years
tiger20
13/5/2013
17:41
Nice tick up today.
rogerbridge
13/5/2013
15:36
maybe so but Biotech Growth beats it on every timescale for performance
harry the haddock
13/5/2013
15:15
IBT is still 11% below NAV.
davebowler
19/4/2013
08:45
Looking like it's trading at NAV now.
affemoose
08/4/2013
14:35
just bought some of these for my sipp. let's hope the recent superb returns continue. had never considered a biotech IT but the returns stood out, looked at them a bit more, the managers are a good experienced pairing and they invest in some massive companies who are market leaders in their sectors. fingers crossed...
harry the haddock
08/4/2013
11:23
Wow - that is the best response to a shareholder query I have ever had. Hats off to frostrow - 14 minutes!!!!!!! See below: "The announcements that you mention relate to issues of new shares to satisfy demand in the market. New shares are issued at a premium to the prevailing net asset value per share to ensure that existing shareholders are not disadvantaged. The funds received are used to make further investments by the Investment manager."
affemoose
08/4/2013
11:16
Whilst the issue of equity does mean there are more share in issue, and shareholders subsequently hold a little less of the company than prior to the issue, the money has been raised at a premium to NAV and therefore benefits all shareholders. The proceeds are then invested into various biotech stocks when the manager deems the time is right and everyone is happy. ITs would never issue shares at a discount to NAV as this would dilute existing holders - so only at a premium, which is the holy grail!
strollingmolby
08/4/2013
10:57
A good point indeed. I am unsure of this is a release of new equity OR the release of equity from treasury. Either way - I assume the proceeds are used to buy new investment stock, thus should be neutral in terms of NAV per share. i do however, hate assumptions. thus ergo to-whit, i shall email their PR people. if I get an answer I shall post it up.
affemoose
06/4/2013
07:27
On BradJeff's point - does this "issue of equity" not dilute our holdings ? - hence yesterdays 2.5 % fall? Who gets the proceeds of sale?
caltonhill
27/3/2013
10:25
Or even better, BB biotech with a 20% discount and 10 times the market cap. :-)
kinbasket
27/3/2013
10:05
This is still at a premium unlike IBT -at a 17% discount to NAV.
davebowler
14/3/2013
13:57
IBT is on a 17% discount to NAV http://www.trustnet.com/Factsheets/Factsheet.aspx?fundCode=ITIBT&univ=T
davebowler
14/3/2013
13:45
help the aged: What is the frequent 'issue of Equity' announcements being made? is this stock being held in treasury? if so - what drives its release?
bradjeff
25/2/2013
09:50
Don't know why you guys are selling - price is going up in line with the NAV.
yiyack3
21/2/2013
08:47
Banked :-)
sawadee3
20/2/2013
16:26
YIjack3 - sounds Ok but it is still very risky . What happens if you have been accumulating stock for a while and hence in a PAPER profit situation but then a bad announcement makes the share price plunge . But this will not happen with an investment trust unless the DOW crashed .
arja
Chat Pages: 14  13  12  11  10  9  8  7  6  5  4  3  Older
ADVFN Advertorial
Your Recent History
LSE
BIOG
Biotech Gr..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210622 02:23:08